Abrupt discontinuation after prolonged use is not recommended
Inhalation doses should be reduced to the lowest effective dose once asthma stability has been achieved.
Concomitant use with strong CYP450 3A4 inhibitors is not recommended.
Oral Corticosteroids :
-Allow at least 1 week before initiating a taper with oral corticosteroid
-Prednisone should be reduced in increments not exceeding mg to 5 mg per day on a weekly basis
-Monitor for signs of asthma instability including serial objective measure of airflow
-Monitor for signs of adrenal insufficiency
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the launch of AirDuo™ RespiClick® and its Authorized Generic, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
Nothing on this website is an offer by . Translations are available, but Dutch is the official language of the country of origin of and therefore rules. Any use of this website, the services provided by and the compliance to applicable local rules and regulations is at your own risk and responsibility and you agree that you entered this website at your own initiative. Product information is only originating from public sources, healthcare providers and/or patient information leaflets and never contains an (own) opinion or advice from , and/or any form of influence on your own choice.
is operated by eMedvertise ., Willemstad, Curacao, Kingdom of the Netherlands. For payment purposes Healthrock Ltd., 11-12 St. James's Square, London, United Kingdom, SW1Y 4LB, registration number 09056454 can be used.